J.P. Morgan analyst Anupam Rama maintained a Buy rating on AnaptysBio today and set a price target of $80.00. The company’s shares opened today at $28.15. Take advantage of TipRanks Premium at 50% off ...

Vir Biotechnology has a strong cash position and is poised to generate definitive data in antivirals and oncology, making ...

Iova stock jumps 31% amid FDA setback for rival, short squeeze buzz, and rising momentum for Amtagvi melanoma therapy.

Northern Trust Corp (NTRS) is expected to report $2.05 for 2Q. Otis Worldwide Corp (OTIS) is expected to report $0.93 for 2Q. PROG Holdings Inc (PRG) is expected to report $0.74 for 2Q. Pacific ...

Replimune (REPL) stock plummeted on Tuesday after the biotechnology company received a Complete Response Letter (CRL) from ...

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

European shares were mostly lower today. The eurozone's STOXX 600 slipped 0.48%, while Spain's IBEX 35 Index fell 0.35%.

Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 0.11%, Hong Kong's Hang Seng gaining 0.54%, China's ...

Investing.com -- Replimune Group, Inc. (NASDAQ: REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...